A phase II trial of oral S-1 combined with gemcitabine in patients with unresectable biliary tract cancer
Kenji Nakamura(Chiba University), Toshio Tsuyuguchi(Chiba University), Tanetoshi Hara(Chiba University), Ryosaku Azemoto(Chiba University), Tadamichi Denda(Chiba Cancer Center), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Tomoaki Ishihara(RIKEN), Kazuaki Sudo(Chiba University)
Cited by 5
Related Papers
Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines
|Journal of Hepato-Biliary-Pancreatic Surgery|2007|489
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2<sup>nd</sup> English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|300
Evidence-based clinical practice guidelines for cholelithiasis 2016
|Journal of Gastroenterology|2016|262